Vicinitas Therapeutics utilizes its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore levels of degraded proteins linked to cancer and genetic disorders. This technology targets protein instability and haploinsufficiency, providing healthcare professionals with novel therapeutic options.
Funding
$65M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, including cancers and genetic disorders, are caused by reduced levels of specific proteins within cells. Current therapeutic approaches often fail to address these conditions effectively because they do not directly restore the levels of these degraded proteins. This protein instability and haploinsufficiency limit treatment options for healthcare professionals.
Solution
Vicinitas Therapeutics is developing a new class of medicines using its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform. This technology works by selectively targeting and inhibiting deubiquitinase (DUB) enzymes, which are responsible for removing ubiquitin tags from proteins and marking them for degradation. By inhibiting these DUBs, the DUBTAC platform prevents the degradation of specific target proteins, thereby restoring their levels within the cell. This approach aims to address diseases caused by protein instability and haploinsufficiency, offering a novel therapeutic strategy.
Target Audience
The primary target audience includes healthcare professionals seeking novel therapeutic options for diseases caused by protein instability and haploinsufficiency, as well as patients suffering from these conditions.
Features
- DUBTAC platform technology for targeted protein stabilization.
- Selective targeting of deubiquitinase (DUB) enzymes.
- Restoration of protein levels in cells affected by degradation.
- Potential application in cancer and genetic disorders.